UBE2C and adrenal cortex carcinoma: Compared early clinical stage I + II to III + IV, the UBE2C expression level was significantly increased in the terminal stage in 8 cancer types including ACC (Figure 3(a)), HNSC (Figure 3(b)), KICH (Figure 3(c)), KIRC (Figure 3(d)), KIRP (Figure 3(e)), LIHC (Figure 3(f)), LUSC (Figure 3(g)), and TGCT (Figure 3(h)) indicating that UBE2C might be a terminal biomarker in these cancer types.